Literature DB >> 8761963

Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells.

P D Prasad1, B J Hoffmans, A J Moe, C H Smith, F H Leibach, V Ganapathy.   

Abstract

We investigated the functional expression of the plasma membrane serotonin transporter and the vesicular monoamine transporter in choriocarcinoma cells and normal trophoblasts. The RBL 2H3 cells, a rat basophilic leukaemia cell line, which express both transporters were used for comparison. The choriocarcinoma cells JAr and BeWo were found to possess the plasma membrane serotonin transporter as assessed by the presence of serotonin transport activity in intact cells that was Na(+)-dependent and was sensitive to inhibition by tricyclic and non-tricyclic antidepressants. The activity of the vesicular monoamine transporter in these cells was determined by measuring serotonin transport in digitonin-permeabilized cells. The transport in permeabilized cells was very slow, was not stimulated by ATP and was insensitive to inhibition by reserpine. Under similar conditions, the vesicular monoamine transporter activity was demonstrable in RBL cells, which was stimulated by ATP and was inhibitable by reserpine, bafilomycin A1 (an inhibitor of the V-type H(+)-pump) and carbonyl cyanide p-trifluoromethoxy phenylhydrazone (a protonophore which dissipates transmembrane H+ gradients). In corroboration with these findings, mRNA transcripts hybridizable to the vesicular monoamine transporter cDNA probe were detectable in RBL cells but not in JAr choriocarcinoma cells. Similarly, there was no evidence for the expression of the vesicular monoamine transporter as assessed by Northern blot analysis in normal trophoblasts which were maintained in culture to differentiate to form multinucleated syncytial cells. It is concluded that the trophoblasts and choriocarcinoma cells express the plasma membrane serotonin transporter but not the vesicular monoamine transporter.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761963     DOI: 10.1016/s0143-4004(96)90039-9

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  12 in total

Review 1.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 2.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

3.  Association of MAOA, 5-HTT, and NET promoter polymorphisms with gene expression and protein activity in human placentas.

Authors:  Huiping Zhang; Graeme N Smith; Xudong Liu; Jeanette J A Holden
Journal:  Physiol Genomics       Date:  2010-03-23       Impact factor: 3.107

4.  In vitro models for studying trophoblast transcellular transport.

Authors:  Claudia J Bode; Hong Jin; Erik Rytting; Peter S Silverstein; Amber M Young; Kenneth L Audus
Journal:  Methods Mol Med       Date:  2006

5.  Disrupted placental serotonin synthetic pathway and increased placental serotonin: Potential implications in the pathogenesis of human fetal growth restriction.

Authors:  Suveena Ranzil; Stacey Ellery; David W Walker; Cathy Vaillancourt; Nadia Alfaidy; Alexander Bonnin; Anthony Borg; Euan M Wallace; Peter R Ebeling; Jan Jaap Erwich; Padma Murthi
Journal:  Placenta       Date:  2019-05-23       Impact factor: 3.481

6.  Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior.

Authors:  Jeremy Veenstra-VanderWeele; Christopher L Muller; Hideki Iwamoto; Jennifer E Sauer; W Anthony Owens; Charisma R Shah; Jordan Cohen; Padmanabhan Mannangatti; Tammy Jessen; Brent J Thompson; Ran Ye; Travis M Kerr; Ana M Carneiro; Jacqueline N Crawley; Elaine Sanders-Bush; Douglas G McMahon; Sammanda Ramamoorthy; Lynette C Daws; James S Sutcliffe; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 7.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

8.  Serotonin homeostasis in the materno-foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta.

Authors:  Rona Karahoda; Hana Horackova; Petr Kastner; Andreas Matthios; Lukas Cerveny; Radim Kucera; Marian Kacerovsky; Jurjen Duintjer Tebbens; Alexandre Bonnin; Cilia Abad; Frantisek Staud
Journal:  Acta Physiol (Oxf)       Date:  2020-05-18       Impact factor: 6.311

9.  Development of serotonin transporter reuptake inhibition assays using JAR cells.

Authors:  Ann M Decker; Bruce E Blough
Journal:  J Pharmacol Toxicol Methods       Date:  2018-03-16       Impact factor: 1.950

Review 10.  Changes in the physiological roles of neurotransmitters during individual development.

Authors:  G A Buznikov; J M Lauder
Journal:  Neurosci Behav Physiol       Date:  1999 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.